Quantcast

Latest Cetuximab Stories

2011-03-01 15:00:00

REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations. This study was published in the March 1, 2011...

2011-03-01 07:00:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of preclinical data on PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), at the American Association of Cancer Research (AACR) Special Conference "Targeting PI3K/mTOR Signaling." PX-866 is an oral, small molecule compound designed to inhibit the activity of PI3K, a component of an important cell survival signaling pathway. Results presented at the...

2011-01-20 16:00:00

MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea. "The overall findings of the study are...

2011-01-20 00:00:49

Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN Calgary, Alberta (Vocus/PRWEB) January 18, 2011 Colorectal cancer is the third leading cause of cancer death among both men and women in the US. The American Cancer Society estimates that nearly 143,000 Americans were diagnosed with colorectal cancer and an estimated 51,370 died from the disease in 2010. Calgary-based biotechnology...

2010-12-20 07:00:00

SEATTLE, WA, Dec. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux(R)). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The primary objective of the Phase 1 dose-escalation portion of the trial is to...

2010-12-16 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to...

2010-12-02 07:00:00

BURLINGTON, Mass., Dec. 2, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the testing rate for epidermal growth factor receptor (EGFR) mutation--a predictor of response to Genentech/Roche/OSI/Chugai's EGFR inhibitor Tarceva--in non-small-cell lung cancer (NSCLC) patients will increase by approximately 50 percent over the next 12 months, according to surveyed U.S. oncologists. In line with...

2010-11-04 13:12:27

Stereotactic body radiotherapy (SBRT), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, may effectively control and treat head and neck cancers when combined with the chemotherapy Cetuximab, according to researchers from UPCI. The results of the research will be presented today at the American Society for Radiation Oncology (ASTRO) annual meeting in San Diego. The study, led by Dwight...

2010-10-28 22:05:14

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010. Researchers said they don't know why this variant site, a microRNA binding site that should allow appropriate regulation of the KRAS gene, exhibited a Dr. Jekyll and Mr. Hyde duality....

2010-10-27 02:21:47

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA. "Recent retrospective correlative analyses of...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.